Li, N., Bullement, A. orcid.org/0000-0001-7091-0972, McMordie, S. et al. (2 more authors) (2019) RO4 Cost-effectiveness analysis of rFVIIIFc, PEGylated rFVIII, and emicizumab for the prophylactic treatment of severe hemophilia A patients without inhibitors in the United States. In: Value in Health. ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, 18-22 May 2019, New Orleans, LA, USA. Elsevier , S389.
Metadata
Item Type: | Proceedings Paper |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2019 The Authors. For re-use permissions please contact the authors. |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 04 Feb 2021 11:13 |
Last Modified: | 04 Feb 2021 16:34 |
Status: | Published |
Publisher: | Elsevier |
Identification Number: | 10.1016/j.jval.2019.04.1898 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:169378 |